SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001714899-22-000105
Filing Date
2022-07-05
Accepted
2022-07-05 08:01:28
Documents
12
Period of Report
2022-07-04
Items
Item 7.01: Regulation FD Disclosure

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20220704.htm   iXBRL 8-K 39127
  Complete submission text file 0001714899-22-000105.txt   175201

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20220704.xsd EX-101.SCH 1932
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20220704_lab.xml EX-101.LAB 23832
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20220704_pre.xml EX-101.PRE 12528
6 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20220704_htm.xml XML 10926
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8548
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

IRS No.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 221063214
SIC: 2836 Biological Products, (No Diagnostic Substances)